or 1259

Levosimendan (OR1259) 是一种钙增敏剂，通过以钙依赖性方式与心肌肌钙蛋白 C 结合，增加肌细胞对钙的敏感性来发挥其作用，可治疗急性失代偿性充血性心力衰竭。

Transdermal Peptide is a 11-amino acid peptide, binds to Na+ K+-ATPase beta-subunit (ATP1B1), and enhances the transdermal delivery of many macromolecules. Transdermal Peptide (TD1) binds to ATP1B1, and mainly interacts with the C-terminus of ATP1B1 in yeast and mammalian cells. The interaction affects the expression and localization of ATP1B1 and epidermal structure, but can be antagonized by the exogenous competitor ATP1B1 or be inhibited by ouabain. Inhibition of Transdermal Peptide binding to ATP1B1 causes decreased delivery of macromolecular drugs across the skin[1]. [1]. Wang C, et al. Role of the Na(+) K(+)-ATPase beta-subunit in peptide-mediated transdermal drug delivery. Mol Pharm. 2015 Apr 6;12(4):1259-67.